<div id="readability-page-1"><p>Noble Financial analyst Robert LeBoyer reiterated a Buy rating on MAIA Biotechnology, Inc. yesterday and set a price target of $14.00. The company’s shares closed yesterday at $1.23.</p><h3>Claim 50% Off TipRanks Premium and Invest with Confidence </h3><ul><li>Unlock  hedge-fund level data  and  powerful investing tools  designed to help you make smarter, sharper decisions  </li><li> Stay ahead of the market with  the latest news and analysis  so your portfolio is always positioned for maximum potential</li></ul> <p>According to TipRanks, LeBoyer is an analyst with an average return of <span>-11.7%</span> and a 27.76% success rate. LeBoyer covers the Healthcare sector, focusing on stocks such as Gyre Therapeutics, Ocugen, and Oncology Institute.</p> <p>MAIA Biotechnology, Inc. has an analyst consensus of Moderate Buy, with a price target consensus of $14.00.</p></div>

MAIA

<p>Noble Financial analyst Robert LeBoyer reiterated a Buy rating for MAIA Biotechnology, Inc., setting a price target of $14.00. The stock closed at $1.23, with an analyst consensus of Moderate Buy. LeBoyer, who covers the Healthcare sector, has an average return of -11.7% and a 27.76% success rate.</p>

MAIA Biotechnology, Inc. (MAIA) Gets a Buy from Noble Financial